Single-cell profiling of immune cells after neoadjuvant pembrolizumab and chemotherapy in IIIA non-small cell lung cancer (NSCLC)

The combination of immune checkpoint inhibitors (ICIs) with chemotherapy (chemoimmunotherapy) in the neoadjuvant setting have achieved favorable clinical benefits in non-small cell lung cancer (NSCLC), but the mechanism of clinical responses remain unclear. We provide a rich resource of 186,477 indi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hui, Zhenzhen, Zhang, Jiali, Ren, Yulin, Li, Xiaoling, Yan, Cihui, Yu, Wenwen, Wang, Tao, Xiao, Shanshan, Chen, Yulong, Zhang, Ran, Wei, Feng, You, Jian, Ren, Xiubao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279493/
https://www.ncbi.nlm.nih.gov/pubmed/35831283
http://dx.doi.org/10.1038/s41419-022-05057-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279493/
https://www.ncbi.nlm.nih.gov/pubmed/35831283
http://dx.doi.org/10.1038/s41419-022-05057-4

Ejemplares similares